Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/art.39614 http://scihub22266oqcxt.onion/10.1002/art.39614 C4920688!4920688!26814428     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arthritis+Rheumatol 2016 ; 68 (7): 1711-20 Nephropedia Template TP {{tp|p=26814428|t=2016. Trends in Long-Term Outcomes Among Patients with ANCA-Associated Vasculitis with Renal Disease |pdf=|usr=}}{{26814428}} gab.com Text Trends in Long-Term Outcomes Among Patients with ANCA-Associated Vasculitis with Renal Disease JO: Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=26814428 #FOAvip Objective: How advances in the management of ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis (AAV) have impacted long-term outcomes is still unclear. We examined temporal changes over 25 years in long-term clinical outcomes, including the impact of renal function at diagnosis (a potential marker of time to disease detection) and duration of cyclophosphamide use in AAV patients with renal involvement. Methods: ANCA-positive, biopsy-proven patients with AAV diagnosed in 1985?2009 followed in the Glomerular Disease Collaborative Network inception cohort were included. Outcomes included the composite outcome of end-stage renal disease (ESRD) or death as well as relapse. Cox proportional hazard or competing risk regression models were adjusted for potential baseline confounders. Results: Data from 544 patients were included in the analysis. There was a decreasing 5-year risk of ESRD or death over time (log rank test for trend: p < 0.001). After adjustment for baseline characteristics, the risk of relapse was similar across the time periods (test for trend: p = 0.45). Serum creatinine at baseline was the only significant predictor of an increased risk of ESRD or death (HR 1.11 per 1 mg/dL of serum creatinine [95% CI 1.04?1.18], p = 0.002). Conclusion: In patients with renal disease secondary to AAV, over 25 years the risk of ESRD or death has decreased but the risk of relapse has not changed. A higher serum creatinine at diagnosis is associated with a higher risk of ESRD or death, suggesting that earlier disease detection is potentially an important measure to improve outcomes in AAV. Twit Text FOAVip Trends in Long-Term Outcomes Among Patients with ANCA-Associated Vasculitis with Renal Disease ????Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=26814428 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26814428 #FOAvip English Wikipedia <ref>{{Cite pmid|26814428}}</ref> Trends in Long-Term Outcomes Among Patients with ANCA-Associated Vasculitis with Renal Disease #MMPMID26814428 Rhee RL; Hogan SL; Poulton CJ; McGregor JAG; Landis JR; Falk RJ; Merkel PA Arthritis Rheumatol 2016[Jul]; 68 (7): 1711-20 PMID26814428show ga Objective: How advances in the management of ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis (AAV) have impacted long-term outcomes is still unclear. We examined temporal changes over 25 years in long-term clinical outcomes, including the impact of renal function at diagnosis (a potential marker of time to disease detection) and duration of cyclophosphamide use in AAV patients with renal involvement. Methods: ANCA-positive, biopsy-proven patients with AAV diagnosed in 1985?2009 followed in the Glomerular Disease Collaborative Network inception cohort were included. Outcomes included the composite outcome of end-stage renal disease (ESRD) or death as well as relapse. Cox proportional hazard or competing risk regression models were adjusted for potential baseline confounders. Results: Data from 544 patients were included in the analysis. There was a decreasing 5-year risk of ESRD or death over time (log rank test for trend: p < 0.001). After adjustment for baseline characteristics, the risk of relapse was similar across the time periods (test for trend: p = 0.45). Serum creatinine at baseline was the only significant predictor of an increased risk of ESRD or death (HR 1.11 per 1 mg/dL of serum creatinine [95% CI 1.04?1.18], p = 0.002). Conclusion: In patients with renal disease secondary to AAV, over 25 years the risk of ESRD or death has decreased but the risk of relapse has not changed. A higher serum creatinine at diagnosis is associated with a higher risk of ESRD or death, suggesting that earlier disease detection is potentially an important measure to improve outcomes in AAV. äTrends in Long-Term Outcomes Among Patients with ANCA-Associated Vascu(epmc).pdf DeepDyve Pubget Overpricing